Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Operating Leases (2019 - 2025)

Editas Medicine (EDIT) has disclosed Operating Leases for 7 consecutive years, with $13.6 million as the latest value for Q3 2025.

  • Quarterly Operating Leases fell 38.61% to $13.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $13.6 million through Sep 2025, down 38.61% year-over-year, with the annual reading at $20.4 million for FY2024, 16.38% down from the prior year.
  • Operating Leases for Q3 2025 was $13.6 million at Editas Medicine, down from $15.0 million in the prior quarter.
  • The five-year high for Operating Leases was $32.9 million in Q4 2022, with the low at $9.3 million in Q3 2022.
  • Average Operating Leases over 5 years is $19.9 million, with a median of $20.5 million recorded in 2024.
  • The sharpest move saw Operating Leases tumbled 52.5% in 2022, then soared 167.13% in 2023.
  • Over 5 years, Operating Leases stood at $16.1 million in 2021, then surged by 104.52% to $32.9 million in 2022, then dropped by 25.84% to $24.4 million in 2023, then decreased by 16.38% to $20.4 million in 2024, then tumbled by 33.44% to $13.6 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $13.6 million, $15.0 million, and $18.0 million for Q3 2025, Q2 2025, and Q1 2025 respectively.